ITMI20021040A1 - Composizioni farmaceutiche iniettabili di un derivato antracenedionico ad attivita' antitumorale - Google Patents

Composizioni farmaceutiche iniettabili di un derivato antracenedionico ad attivita' antitumorale

Info

Publication number
ITMI20021040A1
ITMI20021040A1 IT2002MI001040A ITMI20021040A ITMI20021040A1 IT MI20021040 A1 ITMI20021040 A1 IT MI20021040A1 IT 2002MI001040 A IT2002MI001040 A IT 2002MI001040A IT MI20021040 A ITMI20021040 A IT MI20021040A IT MI20021040 A1 ITMI20021040 A1 IT MI20021040A1
Authority
IT
Italy
Prior art keywords
pharmaceutical compositions
injectable pharmaceutical
anthrocenedional
derivative
tumor activity
Prior art date
Application number
IT2002MI001040A
Other languages
English (en)
Inventor
Valeria Livi
Alberto Bernareggi
Original Assignee
Novuspharma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novuspharma Spa filed Critical Novuspharma Spa
Priority to IT2002MI001040A priority Critical patent/ITMI20021040A1/it
Publication of ITMI20021040A0 publication Critical patent/ITMI20021040A0/it
Priority to ES03729997T priority patent/ES2298521T3/es
Priority to PCT/EP2003/004871 priority patent/WO2003097101A1/en
Priority to AT03729997T priority patent/ATE381944T1/de
Priority to MXPA04011348A priority patent/MXPA04011348A/es
Priority to CA2486001A priority patent/CA2486001C/en
Priority to US10/514,301 priority patent/US20060199831A1/en
Priority to DE60318310T priority patent/DE60318310T2/de
Priority to AU2003240613A priority patent/AU2003240613A1/en
Priority to JP2004505097A priority patent/JP4624780B2/ja
Priority to EP03729997A priority patent/EP1503797B1/en
Publication of ITMI20021040A1 publication Critical patent/ITMI20021040A1/it
Priority to US12/964,861 priority patent/US9211262B2/en
Priority to FR12C0064C priority patent/FR12C0064I2/fr
Priority to US14/937,689 priority patent/US20160256557A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
IT2002MI001040A 2002-05-16 2002-05-16 Composizioni farmaceutiche iniettabili di un derivato antracenedionico ad attivita' antitumorale ITMI20021040A1 (it)

Priority Applications (14)

Application Number Priority Date Filing Date Title
IT2002MI001040A ITMI20021040A1 (it) 2002-05-16 2002-05-16 Composizioni farmaceutiche iniettabili di un derivato antracenedionico ad attivita' antitumorale
EP03729997A EP1503797B1 (en) 2002-05-16 2003-05-09 Injectable pharmaceutical compositions of an anthracenedione derivative with anti-tumoral activity
US10/514,301 US20060199831A1 (en) 2002-05-16 2003-05-09 Injectable pharmaceutical compositions of an anthracenedione derivative with anti-tumoral activity
AU2003240613A AU2003240613A1 (en) 2002-05-16 2003-05-09 Injectable pharmaceutical compositions of an anthracenedione derivative with anti-tumoral activity
AT03729997T ATE381944T1 (de) 2002-05-16 2003-05-09 Injizierbare arzneimittel die ein anthracendionderivat, mit antitumoraktivität, enthalten
MXPA04011348A MXPA04011348A (es) 2002-05-16 2003-05-09 Composiciones farmaceuticas inyectables de un derivado de antracendiona con actividad antitumoral.
CA2486001A CA2486001C (en) 2002-05-16 2003-05-09 Injectable pharmaceutical compositions of an anthracenedione derivative with anti-tumoral activity
ES03729997T ES2298521T3 (es) 2002-05-16 2003-05-09 Composiciones farmaceuticas inyectables de un derivado de antracenodiona con actividad antitumoral.
DE60318310T DE60318310T2 (de) 2002-05-16 2003-05-09 Injizierbare arzneimittel die ein anthracendionderivat, mit antitumoraktivität, enthalten
PCT/EP2003/004871 WO2003097101A1 (en) 2002-05-16 2003-05-09 Injectable pharmaceutical compositions of an anthracenedione derivative with anti-tumoral activity
JP2004505097A JP4624780B2 (ja) 2002-05-16 2003-05-09 抗腫瘍活性を有するアントラセンジオン誘導体の注射用医薬組成物
US12/964,861 US9211262B2 (en) 2002-05-16 2010-12-10 Injectable pharmaceutical compositions of an anthracenedione derivative with anti-tumoral activity
FR12C0064C FR12C0064I2 (fr) 2002-05-16 2012-10-25 Compositions pharmaceutiques injectables d'un derive d'anthracenedione avec action anti-tumorale
US14/937,689 US20160256557A1 (en) 2002-05-16 2015-11-10 Injectable pharmaceutical compositions of an anthracenedione derivative with anti-tumoral activity

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT2002MI001040A ITMI20021040A1 (it) 2002-05-16 2002-05-16 Composizioni farmaceutiche iniettabili di un derivato antracenedionico ad attivita' antitumorale

Publications (2)

Publication Number Publication Date
ITMI20021040A0 ITMI20021040A0 (it) 2002-05-16
ITMI20021040A1 true ITMI20021040A1 (it) 2003-11-17

Family

ID=11449903

Family Applications (1)

Application Number Title Priority Date Filing Date
IT2002MI001040A ITMI20021040A1 (it) 2002-05-16 2002-05-16 Composizioni farmaceutiche iniettabili di un derivato antracenedionico ad attivita' antitumorale

Country Status (12)

Country Link
US (3) US20060199831A1 (it)
EP (1) EP1503797B1 (it)
JP (1) JP4624780B2 (it)
AT (1) ATE381944T1 (it)
AU (1) AU2003240613A1 (it)
CA (1) CA2486001C (it)
DE (1) DE60318310T2 (it)
ES (1) ES2298521T3 (it)
FR (1) FR12C0064I2 (it)
IT (1) ITMI20021040A1 (it)
MX (1) MXPA04011348A (it)
WO (1) WO2003097101A1 (it)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2106788A1 (en) * 2008-04-04 2009-10-07 Ipsen Pharma Liquid and freeze dried formulations
CN105769776B (zh) * 2016-03-26 2018-05-11 青岛市肿瘤医院 一种治疗非霍奇金淋巴瘤的冻干组合物及其制备方法
CN108186560A (zh) * 2016-03-26 2018-06-22 夏建明 一种治疗非霍奇金淋巴瘤的注射液及其制备方法
CN105997896B (zh) * 2016-05-28 2019-07-05 长沙秋点兵信息科技有限公司 治疗非霍奇金淋巴瘤的注射用冻干粉及其制备方法
CN106176630B (zh) * 2016-08-03 2019-01-04 湖北丽益医药科技有限公司 一种注射用马来酸匹杉琼无菌粉末的制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3590124A (en) * 1967-06-27 1971-06-29 Us Navy Blood transfusion fluids having reduced turbulent friction properties
JP2690009B2 (ja) * 1986-07-10 1997-12-10 エーザイ 株式会社 セフアロスポリン注射剤
NZ241868A (en) 1991-03-08 1995-05-26 Univ Vermont 6,9-bis(substituted-amino)benzo[g]isoquinoline-5,10-diones, preparation and pharmaceutical compositions thereof
JP3501471B2 (ja) * 1992-06-15 2004-03-02 旭化成ファーマ株式会社 カルシトニン類の安定化組成物および安定化法
JPH08126685A (ja) * 1994-01-26 1996-05-21 Shionogi & Co Ltd デキストラン類の凍結乾燥方法
US5587382A (en) * 1994-03-28 1996-12-24 Boehringer Mannheim Italia, Spa 6,9-bis[(2-aminoethyl) amino]benzo [g]isoquinoline-5,10- dione dimaleate; an aza-anthracenedione with reduced cardiotoxicity
JP2001522833A (ja) * 1997-11-10 2001-11-20 ジー・ディー・サール・アンド・カンパニー 多剤耐性を治療するためのアルキル化イミノ糖類の使用
GB9808922D0 (en) * 1998-04-24 1998-06-24 Cantab Pharmaceuticals Res Ltd Virus preparations
TWI233805B (en) * 1999-07-01 2005-06-11 Fujisawa Pharmaceutical Co Stabilized pharmaceutical composition in lyophilized form as antifungal agent
IT1315253B1 (it) * 1999-10-22 2003-02-03 Novuspharma Spa Preparazione liposomiale di 6,9-bis-(2-amminoetil)ammino|benzog|isochinolin-5,10-dione dimaleato

Also Published As

Publication number Publication date
EP1503797A1 (en) 2005-02-09
ITMI20021040A0 (it) 2002-05-16
ATE381944T1 (de) 2008-01-15
AU2003240613A1 (en) 2003-12-02
MXPA04011348A (es) 2005-08-15
US20160256557A1 (en) 2016-09-08
DE60318310T2 (de) 2008-12-11
JP2005530792A (ja) 2005-10-13
CA2486001A1 (en) 2003-11-27
US20060199831A1 (en) 2006-09-07
CA2486001C (en) 2010-04-13
FR12C0064I2 (fr) 2013-08-16
US20110144147A1 (en) 2011-06-16
WO2003097101A1 (en) 2003-11-27
JP4624780B2 (ja) 2011-02-02
ES2298521T3 (es) 2008-05-16
DE60318310D1 (de) 2008-02-07
US9211262B2 (en) 2015-12-15
FR12C0064I1 (it) 2012-12-14
EP1503797B1 (en) 2007-12-26

Similar Documents

Publication Publication Date Title
GEP20074099B (en) 3-β-D-RIBOFURANO-SYLTHIAZOLO[4,5-d]PYRIDIMINE NUCLEOSIDES AND USES THEREOF
HK1036970A1 (en) Compounds and compositions for delivering active agents.
PT1093819E (pt) Compostos e composicoes para fornecimento de agentes activos
MY125516A (en) Novel composition based on thiazolidinedione and metformin and use
HK1080364A1 (en) Oral pharmaceutical forms of liquid drugs having improved bioavailability
PL350456A1 (en) N−cyanomethylamides as protease inhibitors
IL140930A0 (en) Compounds and compositions for delivering active agents
AU2274201A (en) Compounds and compositions for delivering active agents
HK1065483A1 (en) 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives
MXPA05001607A (es) Forma galenica para suministro de ingredientes activos dirigido al colon.
SG127738A1 (en) Heterocyclic compounds based on n6-substituted adenine, methods of their preparation, their use for preparation of drugs, pharmaceutical preparations containing these compounds
IL153297A0 (en) Compounds and compositions for delivering active agents
MXPA04005038A (es) Solvatos de paclitaxel.
ATE330595T1 (de) Formulierung von aminosäuren und riboflavin zur verringerung der toxischen effekte der zytotoxischen chemotherapie
MXPA04004567A (es) Compuestos y composiciones de fenoxi amina para adminstrar agentes activos.
DK0971717T3 (da) Cytotoksiske aminosukker- og relaterede sukkerderivater af indolopyrrolocarbazoler
FR12C0064I1 (it)
IL157540A0 (en) N-(aryl)-2-arylethenesulphonamides and therapeutic uses thereof
MXPA03005221A (es) Composicion farmaceutica de dronedarona para administracion parenteral.
DK1268522T3 (da) LH-RH-antagonister samt fremstilling deraf og anvendelse deraf som lægemidler
DE69818492D1 (en) 7-methylthiooxomethyl- und 7-methylthiodioxomethyl-paclitaxele
ATE318268T1 (de) Pyrazolyl-substituierte triazolochinoxaline
IT1302289B1 (it) Composizioni farmaceutiche ad attivita' antineoplastica